Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$1.0 - $3.86 $800 - $3,088
800 New
800 $1,000
Q3 2021

Nov 12, 2021

SELL
$1.89 - $8.53 $52,731 - $237,986
-27,900 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$2.46 - $3.14 $28,044 - $35,796
11,400 Added 69.09%
27,900 $74,000
Q1 2021

May 14, 2021

BUY
$2.86 - $4.77 $47,190 - $78,705
16,500 New
16,500 $51,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $223M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Natixis Portfolio

Follow Natixis and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.